Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model

Schizophrenia Research

Volumn 108, Issue 1-3, 2009, Pages 127-133

  Chintoh, Araba F ^a,b   Mann, Steve W ^a,b   Lam, Loretta ^a   Giacca, Adria ^a   Fletcher, Paul ^b,c   Nobrega, Jose ^a,b   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical antipsychotics; Clozapine; Haloperidol; Insulin resistance; Insulin secretion; Metabolic; Olanzapine; Risperidone; Ziprasidone

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETOGENESIS; GLUCONEOGENESIS; GLUCOSE INFUSION; GLUCOSE UTILIZATION; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MALE; METABOLIC PARAMETERS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; WEIGHT GAIN;

EID: 60249097928     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.12.012     Document Type: Article

References (36)

1. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., and Bergman R.N. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 3 (2005) 862-871
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 11 (1999) 1686-1696
3. Assie M.B., Carilla-Durand E., Bardin L., Maraval M., Aliaga M., Malfetes N., Barbara M., and Newman-Tancredi A. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur. J. Pharmacol. 592 1-3 (2008) 160-166
4. Baptista T., de Baptista E.A., Ying Kin N.M., Beaulieu S., Walker D., Joober R., Lalonde J., and Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res. 957 1 (2002) 144-151
5. Baptista T., de Baptista E.A., Lalonde J., Plamondon J., Kin N.M., Beaulieu S., Joober R., and Richard D. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 8 (2004) 1305-1311
6. Choi S., DiSilvio B., Unangst J., and Fernstrom J.D. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci. 81 12 (2007) 1024-1030
7. Cincotta A.H., Schiller B.C., and Meier A.H. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 40 6 (1991) 639-644
8. De Luca V., Muller D.J., Hwang R., Lieberman J.A., Volavka J., Meltzer H.Y., and Kennedy J.L. HTR2C haplotypes and antipsychotic-induced weight gain: X-linked multimarker analysis. Hum. Psychopharmacol. 22 7 (2007) 463-467
9. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 19 3 (1996) 278-286
10. Emsley R., and Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 7 2 (2004) 219-238
11. Finegood D.T., Bergman R.N., and Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36 (1987) 914-924
12. Henderson D.C., and Doraiswamy P.M. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J. Clin. Psychiatry 69 Suppl 1 (2008) 32-44
13. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., Anderson E.J., Allison D.B., Daley T.B., Schoenfeld D., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62 1 (2005) 19-28
14. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., and Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32 2 (2007) 289-297
15. Jorgensen E.A., Vogelsang T.W., Knigge U., Watanabe T., Warberg J., and Kjaer A. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrinology 83 5-6 (2006) 289-294
16. Kamran A., Doraiswamy P.M., Jane J.L., Hammett E.B., and Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am. J. Psychiatry 151 9 (1994) 1395
17. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153 4 (1996) 466-476
18. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 2 (2003) 625-631
19. King B.M. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol. Behav. 87 2 (2006) 221-244
20. Koval M.S., Rames L.J., and Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am. J. Psychiatry 151 10 (1994) 1520-1521
21. Lin E.J., Lee N.J., Slack K., Karl T., Duffy L., O'Brien E., Matsumoto I., Dedova I., Herzog H., and Sainsbury A. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 51 7-8 (2006) 1129-1136
22. Malhotra A.K., Litman R.E., and Pickar D. Adverse effects of antipsychotic drugs. Drug Safety 9 6 (1993) 429-436
23. Miller D.D., Ellingrod V.L., Holman T.L., Buckley P.F., and Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 133B 1 (2005) 97-100
24. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
25. Nonogaki K., Strack A.M., Dallman M.F., and Tecott L.H. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 4 10 (1998) 1152-1156
26. Poyurovsky M., Pashinian A., Levi A., Weizman R., and Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int. Clin. Psychopharmacol. 20 2 (2005) 101-103
27. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr. Scand. 105 3 (2002) 235-236
28. Ramaswamy K., Kozma C.M., and Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Safety 30 7 (2007) 589-599
29. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin. Psychiatry 60 Suppl 10 (1999) 5-14
30. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., and Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 280 44 (2005) 36824-36832
31. Savoy, Y.E., Ashton, M.A., Miller, M.W., Nedza, F.M., Spracklin, D.K., Hawthorn, M.H., Rollema, H., Matos, F.F., Hajos-Korcsok, E., in press. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr. Bull. [14 Aug 2008 Electronic publication ahead of print].
32. Silvestre J.S., and Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find. Exp. Clin. Pharmacol. 27 5 (2005) 289-304
33. Stetten D., Welt I.D., Ingle D.J., and Moreley E.H. Rates of glucose production and oxidation in normal and diabetic rats. J. Biol. Chem. 192 (1951) 817-830
34. Uwaifo G.I., Parikh S.J., Keil M., Elberg J., Chin J., and Yanovski J.A. Comparison of insulin sensitivity, clearance and secretion estimates using euglycemic and hyperglycemic clamps. J. Clin. Endocrinol. Metab. 87 6 (2002) 2899-2905
35. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., and Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 60 6 (1999) 358-363
36. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., and Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 187 (2005) 537-543